Gradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).

Small- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMAB’s flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.

AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a €21m Series A financing.

The 9th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.

Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory diseases.

 Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect.

The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.

As resource-poor biotech start-ups are the drivers of innovation in the biotech sector, partnering with Big Pharma is essential to survive in a competitive environment. Yet, how to do most effectively? The most often held pharma partnering conference worldwide, euroPLX, provides a plausible answer.

Krakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer.

 

The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.